-->

Ivermectin in COVID-19

Ivermectin in COVID-19

We regard ivermectin as a core medication in the prevention and treatment of COVID-19. For comprehensive information on ivermectin please refer to our  Review of the Emerging Evidence Supporting the Use of Ivermectin in the Prophylaxis and Treatment of COVID-19 and the included references.

These pages contain the scientific rationale that justifies the use of ivermectin in COVID-19.

For PATIENTS AND RELATIVES, please review our HELP PAGES. There you can find information on how to find physicians that prescribe ivermectin as well as information you can share with your primary care physician in the event they have not yet been made aware of the current evidence in support of ivermectin’s efficacy in COVID-19 prevention and treatment.

Ivermectin is a well-known, FDA-approved anti-parasite drug that has been used successfully for more than four decades to treat onchocerciasis “river blindness” and other parasitic diseases. It is one of the safest drugs known. It is on the WHO’s list of essential medicines, has been given 3.7 billion times around the globe, and has won the Nobel prize for its global and historic impacts in eradicating endemic parasitic infections in many parts of the world. Our medical discovery of a rapidly growing published medical evidence base, demonstrating ivermectin’s unique and highly potent ability to inhibit SARS-CoV-2 replication and to suppress inflammation, prompted our team to use ivermectin for prevention and treatment in all stages of COVID-19. Ivermectin is not yet FDA-approved for the treatment of COVID-19, but on Jan 14, 2021, the NIH changed their recommendation for the use of ivermectin in COVID-19 from “against” to “neutral”. (see our  press release).

In March 2020 we created our life-saving  MATH+ Hospital Treatment Protocol for COVID-19, which is intended for hospitalized patients. In October 2020 we developed the  I-MASK+ Prophylaxis & Early Outpatient Treatment Protocol for COVID-19, which is designed for use as a prophylaxis and in early outpatient treatment, for those who test positive for COVID-19. The protocols complement each other, and both are physiologic-based combination treatment regimens developed by leaders in critical care medicine. All the component medicines are FDA-approved, inexpensive, readily available and have been used for decades with well-established safety profiles. Both protocols are available in several languages.

Recent studies and clinical trials on ivermectin

For an up-to-date overview of all published studies on ivermectin in the treatment and prevention of COVID-19 we recommend visiting  c19ivermectin.com; in addition, a meta-analysis of all studies can be found at  ivmeta.com (constantly updated).

A majority of the studies (until January 12, 2021) were included in our comprehensive  Review of the Emerging Evidence Supporting the Use of Ivermectin in the Prophylaxis and Treatment of COVID-19, and a brief summary of the studies at that time can be found in the accompanying  One-page summary of the scientific review on ivermectin.

 


Source: Database of all ivermectin COVID-19 studies – www.c19ivermectin.com – (constantly updated)

 


Source: Global ivermectin adoption for COVID-19 – ivmstatus.com (constantly updated)

Further information

FLCCC Alliance review on ivermectin in COVID-19